Wed, Jul 23, 2014, 11:10 AM EDT - U.S. Markets close in 4 hrs 50 mins

Recent

% | $
Click the to save as a favorite.

Seattle Genetics Inc. Message Board

  • llabtechtwo llabtechtwo Feb 5, 2013 12:03 PM Flag

    Earnings

    Can't wait it is going to be interesting to see where we sit at this point in time!! Of course any revenue generated by adcetris is in its infancy!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This this could be good? Over the last year and a half it's been buy the rumor-sell the news. This is at least different.
      I still think they could book some of the current milestones as income this quarter and show a profit. The truth is they ARE profitable for 2012 as measured by cash flow. I hope they find a way to communicate that.
      We will either see $25 or $35 in the next week. I'm hoping for the buying opportunity but I think it will go higher instead. Today may be the day to buy?
      We will have to see if they are still conservative on the 2013 revenue guidance.

    • More money is going to be coming from joint ventures with big pharma. The use of a proven technology is going to add to the list of companies looking for a target. New ones are coming up all of the time and seem to have efficacy in areas beyond oncology.
      The earnings will continue to grow and allow for nondilutive investments with drugs that SGEN chooses to develop or partner with. Some milestones should be coming and added revenue from the Canadians. Time frame to add more patients and introduction into the Canadian market should start shortly and accretive to earnings.
      Only just beginning to be recognized but the growth will continue.

      BH

 
SGEN
35.3199+1.0599(+3.09%)11:09 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.